NEW YORK (GenomeWeb News) – Insight Genetics today announced it was awarded a $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute to continue development of a diagnostic test aimed at non-small cell lung cancer.

The Fast Track contract will go toward the further development of a panel of assays for identifying and characterizing ongogenic ROS1, RET, and DEPDC1 in a population of NSCLC patients who are triple negative for mutations in EGFR, KRAS, or ALK, the Nashville, Tenn.-based company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.